Table 2.
Survival based on homozygous MCPH1 deletion status.
| Cancer site | Number of patients with homozygous deletion | Number of patients without homozygous deletion | Overall survival | Disease free survival | ||||
|---|---|---|---|---|---|---|---|---|
| Log rank | 95% CI | P value | Log rank | 95% CI | P value | |||
| Bladder | 26 | 297 | 1.42 | 0.8179–2.797 | 0.19 | 2.44 | 1.810–8.243 | < 0.01 |
| Prostate | 49 | 449 | 1.71 | 0.1502–26.49 | 0.61 | 1.84 | 1.046–4.636 | 0.04 |
| Esophagus | 5 | 179 | 0.84 | 0.1387–5.258 | 0.87 | 17.01 | 113,231–1.241e8 | < 0.01 |
| Colorectal | 39 | 507 | 1.6 | 0.8682–3.710 | 0.12 | 1.91 | 1.20–5.068 | 0.03 |
| Ovarian | 42 | 549 | 0.76 | 0.5330–1.149 | 0.21 | 0.93 | 0.6178–1.398 | 0.73 |
| Lung squamous | 35 | 466 | 0.95 | 0.5869–1.550 | 0.85 | 1.4 | 0.7024–3.126 | 0.3 |
| Lung Adeno | 30 | 487 | 0.85 | 0.4758–1.564 | 0.63 | 0.77 | 0.4364–1.440 | 0.45 |
| Liver | 29 | 341 | 1.66 | 0.9105–3.977 | 0.09 | 0.78 | 0.1133–4.968 | 0.79 |
| Stomach | 12 | 429 | 0.62 | 0.2740–1.689 | 0.41 | 0.23 | 0.1705–1.195 | 0.11 |
| Breast | 12 | 142 | 1.02 | 0.5650–1.858 | 0.94 | 0.63 | 0.3274–1.405 | 0.3 |
| Melanoma | 7 | 310 | 1.75 | 0.5748–7.709 | 0.26 | 1.52 | 0.4989–5.612 | 0.41 |
| Pancreas | 2 | 183 | 2.44 | 0.4807–36.23 | 0.2 | 1.33 | 0.1442–13.48 | 0.77 |
| Uterine | 24 | 515 | 1.61 | 0.7079–4.728 | 0.22 | 1.19 | 0.4559–3.178 | 0.71 |
| Sarcoma | 7 | 250 | 0.72 | 0.2278–2.516 | 0.65 | 0.9 | 0.3502–2.333 | 0.84 |
| Head and neck | 19 | 503 | 0.76 | 0.4030–1.517 | 0.47 | 1.09 | 0.4950–2.395 | 0.83 |
| RCC | 7 | 521 | 1.38 | 0.3848–5.559 | 0.58 | 2.11 | 0.5811–15.57 | 0.19 |
| Cervical | 7 | 288 | 3.83 | 1.740–138.9 | 0.01 | 3.29 | 0.7681–112.5 | 0.08 |
| Low Grade Glioma | 0 | 475 | ||||||
| PCPG | 0 | 162 | ||||||
| Thyroid | 2 | 483 | 0 | 0.001125–117.6 | 0.73 | 0 | 0.005156–25.94 | 0.64 |
| GBM | 1 | 571 | 0.81 | 0.1412–4.860 | 0.84 | 0.67 | 0.1436–3.570 | 0.68 |
| AML | 0 | 64 | ||||||